THE EFFECT OF CIPROFLOXACIN ON THEOPHYLLINE PHARMACOKINETICS IN HEALTHY-SUBJECTS

Citation
Kt. Batty et al., THE EFFECT OF CIPROFLOXACIN ON THEOPHYLLINE PHARMACOKINETICS IN HEALTHY-SUBJECTS, British journal of clinical pharmacology, 39(3), 1995, pp. 305-311
Citations number
32
Categorie Soggetti
Pharmacology & Pharmacy
ISSN journal
03065251
Volume
39
Issue
3
Year of publication
1995
Pages
305 - 311
Database
ISI
SICI code
0306-5251(1995)39:3<305:TEOCOT>2.0.ZU;2-F
Abstract
1 The mechanism of the interaction between ciprofloxacin and theophyll ine was investigated in nine healthy subjects, 2 Subjects were given a single oral dose of theophylline (3.4 mg kg(-1)), before and after 60 h of ciprofloxacin therapy at a dose of 500 mg twice daily. 3 Ciprofl oxacin reduced the oral clearance of theophylline by 19% (-7.73 +/- 6. 42 ml kg(-1) h(-1) (95% confidence limits -12.66, -2.79)). Some subjec ts (group A, n = 4) showed little decrease in clearance (mean 4.4%; -1 .6 +/- 0.7 ml kg(-1) h(-1) (-26, -0.5)), whereas others (group B, n = 5) showed a marked decrease (mean 30%; -12.7 +/- 3.7 mi kg(-1) h(-1) ( -17.2, -8.1)). 4 Comparing groups A and B, the decrease in oral cleara nce of theophylline in group B could not be ascribed to differences in the AUC of ciprofloxacin. Group A subjects showed only slight inhibit ion of l-demethylation (-12.8 +/- 5.5% (-21.5, -4.0)), while group B s ubjects showed a significantly greater inhibition of l-demethylation ( -49.9 +/- 9.8% (-62.1, -37.7)), 3-demethylation (-44.8 +/- 8.6% (-55.4 , -34.1)) and 8-hydroxylation (-27.0 +/- 3.7% (-31.6, -22.4)), 5 The r esults suggest that inter-individual variability in the inhibition of theophylline metabolism by ciprofloxacin can be attributed to inter-in dividual differences in the level of CYP1A2 expression and/or in the d egree of inhibition of hepatic CYP1A2 and CYP3A4. 6 The interaction be tween ciprofloxacin and theophylline can be clinically significant. Ho wever, uniform decrease in the theophylline dose is not warranted beca use there is a negligible change in theophylline clearance when ciprof loxacin is coadministered in a substantial proportion of patients.